Yunus Gurbuz

Yunus Gurbuz

Auto-generated profile, based on publicly available information

Yunus Gurbuz


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2023 in Klimik Dergisi/Klimik Journal
Verified
Journal Article
Open access
BABilgehan Aygen
Bilgehan Aygen
YGYunus Gurbuz
Yunus Gurbuz
RCRiza Aytac Cetinkaya
Riza Aytac Cetinkaya
GCGule Cinar
Gule Cinar
UKUner Kayabas
Uner Kayabas
NDNese Demirturk
Nese Demirturk
Direct-acting antiviral (DAA) drugs have increased the effectiveness of treatment in hepatitis C patients. With the developments in the world and DAA drugs coming into use in our country, the consensus report on the management of hepatitis C virus (HCV) infection has needed to be updated. It was first published in 2014 and updated in 2017 by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases. Here, the Study Group has reviewed every aspect of chronic hepatitis C and revised the consensus report with the updated information. At the end of each topic, the agreed recommendations are summarized, considering the drugs reimbursed in our country.